Literature DB >> 24713380

[Indication and timing of heart valve surgery - summery of the European guidelines].

Simon H Sündermann1, Diana Reser1, Martin Czerny1, Volkmar Falk1.   

Abstract

Most common heart valve diseases in western industrialized nations are the aortic valve stenosis and the mitral valve regurgitation. More seldom are a regurgitation of the aortic valve and mitral valve stenosis. Even more seldom are heart valve diseases of the Tricuspid and the pulmonary valve. The only curative therapy in severe heart valve disease is a surgical intervention. The timing is crucial for the outcome. Especially in asymptomatic patients it's difficult to find the right point of time for intervention due to missing realization of the health status. In 2013, the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC) published guidelines according to the therapy in heart valve disease. Here we want to summarize the recommendations of these guidelines in regards of timing of the surgical intervention.

Entities:  

Keywords:  Guidelines; Herzklappenerkrankungen; Zeitpunkt der Operation; calendrier de l'opération; guidelines; heart valve disease; lignes directrices; timing of the operation; valvulopathie cardiaque

Mesh:

Year:  2014        PMID: 24713380     DOI: 10.1024/1661-8157/a001626

Source DB:  PubMed          Journal:  Praxis (Bern 1994)        ISSN: 1661-8157


  2 in total

1.  Ex vivo 4D visualization of aortic valve dynamics in a murine model with optical coherence tomography.

Authors:  Christian Schnabel; Anett Jannasch; Saskia Faak; Thomas Waldow; Edmund Koch
Journal:  Biomed Opt Express       Date:  2014-11-07       Impact factor: 3.732

2.  Optical coherence tomography and multiphoton microscopy offer new options for the quantification of fibrotic aortic valve disease in ApoE-/- mice.

Authors:  Anett Jannasch; Christian Schnabel; Roberta Galli; Saskia Faak; Petra Büttner; Claudia Dittfeld; Sems Malte Tugtekin; Edmund Koch; Klaus Matschke
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.